Gloria Salvo

Gloria Salvo

Auto-generated profile, based on publicly available information

Gloria Salvo

Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
GSGloria Salvo
Gloria Salvo
PRPedro T. Ramirez
Pedro T. Ramirez
CLCharles F. Levenback
Charles F. Levenback
MMMark F. Munsell
Mark F. Munsell
EEElizabeth D. Euscher
Elizabeth D. Euscher
MFMichael Frumovitz
Michael Frumovitz

1 May 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
EMEster Miralpeix
Ester Miralpeix
ANAlpa M. Nick
Alpa M. Nick
LMLarissa A. Meyer
Larissa A. Meyer
JCJuan Cata
Juan Cata
JLJavier Lasala
Javier Lasala
PRPedro T Ramirez
Pedro T Ramirez

1 March 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
AOAndreas Obermair
Andreas Obermair
RARebecca Asher
Rebecca Asher
RPRene Pareja
Rene Pareja
MFMichael Frumovitz
Michael Frumovitz
ALAldo Lopez
Aldo Lopez
PRPedro T. Ramirez
Pedro T. Ramirez

1 July 2019 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
GSGloria Salvo
Gloria Salvo
AMAntonio Gonzalez Martin
Antonio Gonzalez Martin
NGNaomi R Gonzales
Naomi R Gonzales
MFMichael Frumovitz
Michael Frumovitz
Neuroendocrine carcinomas of the cervix account for less than 2% of all invasive cervical cancers and are classified as low-grade (carcinoid, atypical carcinoid tumor) or high-grade (known as small- and large-cell) neuroendocrine carcinomas. There are increasing data showing that cervical neuroendocrine carcinomas may be associated with the human papillomavirus (HPV), especially HPV18, and most will stain positive for p16. Immunohistochemistry markers such as synaptophysin and CD56 are the most sensitive markers. Although there are no commonly associated mutations, PIK3CA, KRAS, and TP53 are the most frequently found mutations in neuroendocrine tumors. Neuroendocrine cervical carcinomas are exceedingly aggressive tumors with a high tendency for nodal involvement and distant metastases. Age, lymph node metastases, smoking, pure small-cell histology, and tumor size are independent prognostic factors. Overall, the 5-year survival rate is 36% and the median overall survival ranges between 22 and 25 months. Treatment options are often extrapolated from small-cell lung cancer and limited retrospective studies. The preferred treatment is a multimodal approach of surgery, chemoradiation, and systemic chemotherapy. The most common chemotherapy regimen used as initial therapy is a combination of cisplatin and etoposide. In the setting of recurrent disease, a combination of topotecan, paclitaxel, and bevacizumab has demonstrated favorable outcomes. Multicenter tumor registries, such as the Neuroendocrine Cervical Tumor Registry (NeCTuR), are an opportunity to evaluate patterns of disease treatment and oncologic outcomes.

1 December 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
MPMaria Guadalupe Patrono
Maria Guadalupe Patrono
MIMaria D. Iniesta
Maria D. Iniesta
AMAnais Malpica
Anais Malpica
KLKaren H. Lu
Karen H. Lu
RORodrigo Orozco
Rodrigo Orozco
PRPedro T Ramirez
Pedro T Ramirez

1 June 2020 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
GSGloria Salvo
Gloria Salvo
DODiego Odetto
Diego Odetto
RPRene Pareja
Rene Pareja
MFMichael Frumovitz
Michael Frumovitz
PRPedro T Ramirez
Pedro T Ramirez
Recently the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer was published. In this most recent classification, imaging modalities and pathologic information have been added as tools to determine the final stage of the disease. Although there are many merits to this new staging for cervical cancer, including more detailed categorization of early-stage disease as well as information on nodal distribution, the classification falls short in clarifying areas of controversy in the staging system. Many unanswered questions remain and, as such, a number of gaps lead to further debate in the interpretation of relevant clinical data. Factors such as measurement of tumor size, definition of parametrial involvement, ovarian metastases, lower uterine segment extension, lymph node metastasis, and imaging modalities are explored in this review. The goal is to focus on items that deserve further discussion and clarification in the most recent FIGO staging for cervical cancer.